Cardiovascular complications in diabetic kidney disease

Seminars in Dialysis

Volumn 23, Issue 2, 2010, Pages 169-177

  Patel, Tejas ^a   Charytan, David M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; HUMAN; PATHOPHYSIOLOGY; RISK FACTOR; CARDIOVASCULAR DISEASES; COMPLICATION;

CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; HUMANS; RISK FACTORS;

EID: 77953213236     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00704.x     Document Type: Article

References (110)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
2. Incidence and prevalence of ESRD. http://www.usrds.org/slides.htm, Available at , accessed July 30, 2009
3. Medicare enrollees in 2006. http://www.statehealthfacts.org/profileind.Jsp?Cat=6&sub=74&rgn=1, Available at , accessed July 31, 2009
4. Cost of ESRD 2006. http://www.usrds.org/2008/pdf/v2_11_2008.Pdf, Available at , accessed July 31, 2009
5. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
6. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united states medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
8. Incidence and prevalence of ESRD 2008. http://www.Usrds.Org/2008/pdf/v2_02_2008.Pdf, Available at , accessed July 31, 2009
9. McKinlay J, Marceau L. US public health and the 21st century: diabetes mellitus. Lancet 2000, 356:757-761.
10. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
11. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the medicare population. Kidney Int Suppl 2003, 64:S24-S31.
12. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003, 14:2373-2380.
13. Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int 2003, 64:1398-1405.
14. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002, 106:974-980.
15. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
16. Morbidity and mortality in CKD patients: United States renal data system. http://www.usrds.org/2008/pdf/v1_03_2008.Pdf, Available at , accessed July 15, 2009
17. Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005, 46:406-414.
18. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. Am J Cardiol 2008, 101:925-929.
19. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
20. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the choice study. J Am Soc Nephrol 2002, 13:1918-1927.
21. Kalantar-Zadeh K. What is so bad about reverse epidemiology anyway? Semin Dial 2007, 20:593-601.
22. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible " Third great wave" in cardiovascular secondary prevention. Am J Cardiol 2008, 101:4D-13D.
23. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 2008, 73:1406-1412.
24. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005, 68:766-772.
25. Longenecker JC, Klag MJ, Marcovina SM, Powe NR, Fink NE, Giaculli F, Coresh J. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the choice study. Circulation 2002, 106:2812-2818.
26. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007, 71:1036-1043.
27. Suliman ME, Lindholm B, Barany P, Qureshi AR, Stenvinkel P. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 2007, 20:523-529.
28. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997, 349.
29. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
30. Friedman AN, Hunsicker LG, Selhub J, Bostom AG. Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol 2005, 16:3397-3402.
31. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009, 53:138-150.
32. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006, 17:2112-2119.
33. Amann K, Neimeier KA, Schwarz U, Tornig J, Matthias S, Orth SR, Mall G, Ritz E. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 1997, 30:382-388.
34. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005, 293:1737-1745.
35. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
36. Kestenbaum BR, Adeney KL, Boer IH, Ix JH, Shlipak MG, Siscovick DS. Incidence and progression of coronary calcification in chronic kidney disease: the multi-ethnic study of atherosclerosis. Kidney Int 2009, 76:991-998.
37. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007, 2:1241-1248.
38. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004, 65:1790-1794.
39. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1489-1496.
40. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004, 19:2307-2312.
41. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004, 8:54-58.
42. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003, 14:159-168.
43. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005, 16:507-513.
44. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 2004, 66:2022-2031.
45. Bonifacio DL, Malineni K, Kadakia RA, Soman SS, Sandberg KR, McCullough PA. Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk 2001, 8:133-137.
46. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001, 103:1051-1056.
47. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
48. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007, 72:1255-1261.
49. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005, 20:1653-1661.
50. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate renagel evaluation-2 (care-2) study. Am J Kidney Dis 2008, 51:952-965.
51. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 1999, 71:S238-S241.
52. Level C, Lasseur C, Delmas Y, Cazin MC, Vendrely B, Chauveau P, Gosse P, Combe C. Determinants of arterial compliance in patients treated by hemodialysis. Clin Nephrol 2001, 56:435-444.
53. Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, Carvalho AB, Neto EM, Canziani ME. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006, 21:2464-2471.
54. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
55. Huybers S, Bindels RJ. Vascular calcification in chronic kidney disease: new developments in drug therapy. Kidney Int 2007, 72:663-665.
56. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201.
57. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007, 72:792-796.
58. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006, 69:33-43.
59. Drissi H, Pouliot A, Koolloos C, Stein JL, Lian JB, Stein GS, van Wijnen AJ. 1,25-(oh)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002, 274:323-333.
60. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008, 19:1509-1519.
61. Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 2007, 20:139-143.
62. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990, 38:931-936.
63. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron I 1997, 77:37-43.
64. Berlyne GM, Mallick NP. Arterial calcification after vitamin D. Lancet 1969, 1.
65. Kingma JG, Roy PE. Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats. Artery 1988, 16:51-61.
66. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997, 96:1755-1760.
67. Morosetti M, Jankovic L, Palombo G, Cipriani S, Dominijanni S, Balducci A, Splendiani G, Simonetti G, Romagnoli A, Coen G. High-dose calcitriol therapy and progression of cardiac vascular calcifications. J Nephrol 2008, 21:603-608.
68. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008, 19:1239-1246.
69. Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients? Kidney Int 2008, 73:3-5.
70. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (fgf23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 2007, 18:2600-2608.
71. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
72. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
73. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW. Association of serum fetuin-a levels with mortality in dialysis patients. Kidney Int 2007, 72:202-207.
74. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005, 67:2295-2304.
75. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006, 70:2021-2030.
76. Cheema BS. Review article: tackling the survival issue in end-stage renal disease: time to get physical on haemodialysis. Nephrology (Carlton) 2008, 13:560-569.
77. Stack AG, Molony DA, Rives T, Tyson J, Murthy BV. Association of physical activity with mortality in the us dialysis population. Am J Kidney Dis 2005, 45:690-701.
78. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007, 50:602-611.
79. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009, 20:872-881.
80. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009, 103:1359-1363.
81. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
82. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008, 83:870-879.
83. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004, 110:1557-1563.
84. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
85. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
86. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y. Candesartan, an angiotensin ii type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006, 21:2507-2512.
87. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006, 70:1318-1324.
88. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008, 52:501-506.
89. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003, 139:105-112.
90. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
91. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354:1578-1588.
92. Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006, 1:780-786.
93. Tepel M, Van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003, 107:992-995.
94. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (space): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
95. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
96. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
97. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530.
98. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H. Baseline characteristics in the trial to reduce cardiovascular events with Aranesp therapy (treat). Am J Kidney Dis 2009, 54:59-69.
99. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62:245-252.
100. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68:1815-1824.
101. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
102. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45:S1-S153.
103. Wolf M. Active vitamin D and survival. J Am Soc Nephrol 2008, 19:1442-1443.
104. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
105. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999, 33:73-81.
106. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007, 104:16810-16815.
107. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
108. The Primo Study. http://www.clinicaltrials.gov/ct2/show/nct00497146?Term=primo+study&rank=1, Available at , accessed August 16, 2009
109. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int Suppl 2003, 63:S207-S210.
110. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Evaluation of cinacalcet therapy to lower cardiovascular events (evolve): rationale and design overview. Clin J Am Soc Nephrol 2007, 2:898-905.